Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Financing Activities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Cash from Financing Activities for 3 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $101.4 million through Dec 2025, up 41.53% year-over-year, with the annual reading at $101.4 million for FY2025, 41.53% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $1.3 million at Inhibrx Biosciences, up from $352000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $199.9 million in Q3 2023, with the low at $352000.0 in Q3 2025.
  • Average Cash from Financing Activities over 3 years is $53.4 million, with a median of $32.9 million recorded in 2024.
  • Peak annual rise in Cash from Financing Activities hit 157.8% in 2025, while the deepest fall reached 157.8% in 2025.
  • Over 3 years, Cash from Financing Activities stood at $860000.0 in 2023, then surged by 3731.4% to $32.9 million in 2024, then tumbled by 96.19% to $1.3 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $1.3 million, $352000.0, and $99.8 million for Q4 2025, Q3 2025, and Q1 2025 respectively.